Folgen
Frederik Verelst
Frederik Verelst
Director, Vaccines Value Evidence / Health Outcomes, GSK
Bestätigte E-Mail-Adresse bei gsk.com
Titel
Zitiert von
Zitiert von
Jahr
Behavioural change models for infectious disease transmission: a systematic review (2010–2015)
F Verelst, L Willem, P Beutels
Journal of The Royal Society Interface 13 (125), 20160820, 2016
3672016
Indications for healthcare surge capacity in European countries facing an exponential increase in coronavirus disease (COVID-19) cases, March 2020
F Verelst, E Kuylen, P Beutels
Eurosurveillance 25 (13), 2000323, 2020
2212020
Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015)
L Willem, F Verelst, J Bilcke, N Hens, P Beutels
BMC Infectious Diseases 17 (1), 612, 2017
1742017
Individual decisions to vaccinate one's child or oneself: A discrete choice experiment rejecting free-riding motives
F Verelst, L Willem, R Kessels, P Beutels
Social Science & Medicine 207, 106-116, 2018
662018
SOCRATES-CoMix: a platform for timely and open-source contact mixing data during and in between COVID-19 surges and interventions in over 20 European countries
F Verelst, L Hermans, S Vercruysse, A Gimma, P Coletti, JA Backer, ...
BMC medicine 19, 1-7, 2021
472021
Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July–December 2020)
S Valckx, J Crèvecoeur, F Verelst, M Vranckx, G Hendrickx, N Hens, ...
Vaccine 40 (1), 151-161, 2022
412022
Drivers of vaccine decision-making in South Africa: A discrete choice experiment
F Verelst, R Kessels, W Delva, P Beutels, L Willem
Vaccine 37 (15), 2079-2089, 2019
372019
Preferential differences in vaccination decision-making for oneself or one’s child in The Netherlands: a discrete choice experiment
J Hoogink, F Verelst, R Kessels, AJ van Hoek, A Timen, L Willem, ...
BMC Public Health 20, 1-14, 2020
332020
The influence of risk perceptions on close contact frequency during the SARS-CoV-2 pandemic
J Wambua, L Hermans, P Coletti, F Verelst, L Willem, CI Jarvis, A Gimma, ...
Scientific reports 12 (1), 5192, 2022
212022
Workplace influenza vaccination to reduce employee absenteeism: An economic analysis from the employers’ perspective
F Verelst, P Beutels, N Hens, L Willem
Vaccine 39 (14), 2005-2015, 2021
162021
Economic burden of epilepsy in rural Ituri, Democratic Republic of Congo
JNS Fodjo, M Mandro, D Wonya'rossi, Y Inaç, F Ngave, R Lokonda, ...
EClinicalMedicine 9, 60-66, 2019
162019
No Such Thing as a Free-Rider? Understanding Drivers of Childhood and Adult Vaccination through a Multicountry Discrete Choice Experiment
F Verelst, R Kessels, L Willem, P Beutels
Vaccines 9 (3), 264, 2021
152021
Sponsorship bias in base-case values and uncertainty bounds of health economic evaluations? A systematic review of herpes zoster vaccination
J Bilcke, F Verelst, P Beutels
Medical Decision Making 38 (6), 730-745, 2018
142018
Determinants of basic childhood vaccination coverage in European and OECD countries
V Varbanova, F Verelst, N Hens, P Beutels
Human Vaccines & Immunotherapeutics 18 (6), 2123883, 2022
22022
EE331 Leveraging Time-Use Data to Estimate Market and Non-Market Productivity Losses Due to Respiratory Syncytial Virus (RSV) Disease Among Adults Aged≥ 60 Years in the United …
F Verelst, EM La, J Graham, D Molnar
Value in Health 26 (6), S120, 2023
12023
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged≥ 60 years in Japan: results of a Markov model analysis
D Kurai, A Mizukami, V Preckler, F Verelst, D Molnar, T Matsuki, Y Ho, ...
Expert Review of Vaccines 23 (1), 303-311, 2024
2024
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States
D Molnar, EM La, F Verelst, S Poston, J Graham, LA Van Bellinghen, ...
Infectious Diseases and Therapy, 1-18, 2024
2024
EPH45 Assessing the Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Older Adults in the United States (US)
D Molnar, EM La, F Verelst, D Curran, S Poston, LA Van Bellinghen, ...
Value in Health 26 (6), S172, 2023
2023
Different forms of superspreading lead to different outcomes: Heterogeneity in infectiousness and contact behavior relevant for the case of SARS-CoV-2
EJ Kuylen, A Torneri, L Willem, PJK Libin, S Abrams, P Coletti, N Franco, ...
PLOS Computational Biology 18 (8), e1009980, 2022
2022
Ceci n'est pas un lit. Base capacity healthcare matters in a pandemic
P Beutels, F Verelst
The Lancet Regional Health-Europe 2, 100033, 2021
2021
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20